tbuckley/cabot-search huggingface dataset:
Survival Prospects and Circumstances of Death in Contemporary Adult Congenital Heart Disease Patients Under Follow-Up at a Large Tertiary Centre
Authors: Gerhard-Paul Diller, Aleksander Kempny, Rafael Alonso-Gonzalez, Lorna Swan, Anselm Uebing, Wei Li, Sonya Babu-Narayan, Stephen J. Wort, Konstantinos Dimopoulos, Michael A. Gatzoulis
Journal: Circulation (2015)

Adult congenital heart disease (ACHD) patients have ongoing morbidity and reduced long-term survival. Recently, the importance of specialized follow-up at tertiary ACHD centers has been highlighted. We aimed to assess survival prospects and clarify causes of death in a large cohort of patients at a single, tertiary center.We included 6969 adult patients (age 29.9 ± 15.4 years) under follow-up at our institution between 1991 and 2013. Causes of death were ascertained from official death certificates. Survival was compared with the expected survival in the general age- and sex-matched population, and standardized mortality rates were calculated. Over a median follow-up time of 9.1 years (interquartile range, 5.2-14.5), 524 patients died. Leading causes of death were chronic heart failure (42%), pneumonia (10%), sudden-cardiac death (7%), cancer (6%), and hemorrhage (5%), whereas perioperative mortality was comparatively low. Isolated simple defects exhibited mortality rates similar to those in the general population, whereas patients with Eisenmenger syndrome, complex congenital heart disease, and Fontan physiology had much poorer long-term survival (P<0.0001 for all). The probability of cardiac death decreased with increasing patient's age, whereas the proportion of patients dying from noncardiac causes, such as cancer, increased.ACHD patients continue to be afflicted by increased mortality in comparison with the general population as they grow older. Highest mortality rates were observed among patients with complex ACHD, Fontan physiology, and Eisenmenger syndrome. Our data provide an overview over causes of mortality and especially the spectrum of noncardiac causes of death in contemporary ACHD patients.
Surgery for Stage IV Breast Cancer
Authors: Lisa A. Newman
Journal: JAMA Surgery (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Normal-Weight Central Obesity: Implications for Total and Cardiovascular Mortality
Authors: Karine R. Sahakyan, Virend K. Somers, Juan P. Rodriguez-Escudero, David O. Hodge, Rickey E. Carter, Ondrej Sochor, Thais Coutinho, Michael D. Jensen, Véronique L. Roger, Prachi Singh, Francisco Lopez-Jimenez
Journal: Annals of Internal Medicine (2015)

Background: The relationship between central obesity and survival in community-dwelling adults with normal body mass index (BMI) is not well-known. Objective: To examine total and cardiovascular mortality risks associated with central obesity and normal BMI. Design: Stratified multistage probability design. Setting: NHANES III (Third National Health and Nutrition Examination Survey). Participants: 15 184 adults (52.3% women) aged 18 to 90 years. Measurements: Multivariable Cox proportional hazards models were used to evaluate the relationship of obesity patterns defined by BMI and waist-to-hip ratio (WHR) and total and cardiovascular mortality risk after adjustment for confounding factors. Results: Persons with normal-weight central obesity had the worst long-term survival. For example, a man with a normal BMI (22 kg/m2) and central obesity had greater total mortality risk than one with similar BMI but no central obesity (hazard ratio [HR], 1.87 [95% CI, 1.53 to 2.29]), and this man had twice the mortality risk of participants who were overweight or obese according to BMI only (HR, 2.24 [CI, 1.52 to 3.32] and 2.42 [CI, 1.30 to 4.53], respectively). Women with normal-weight central obesity also had a higher mortality risk than those with similar BMI but no central obesity (HR, 1.48 [CI, 1.35 to 1.62]) and those who were obese according to BMI only (HR, 1.32 [CI, 1.15 to 1.51]). Expected survival estimates were consistently lower for those with central obesity when age and BMI were controlled for. Limitations: Body fat distribution was assessed based on anthropometric indicators alone. Information on comorbidities was collected by self-report. Conclusion: Normal-weight central obesity defined by WHR is associated with higher mortality than BMI-defined obesity, particularly in the absence of central fat distribution. Primary Funding Source: National Institutes of Health, American Heart Association, European Regional Development Fund, and Czech Ministry of Health.
Preliminary Report: The Development of the NCCN Comparative Therapeutic Index™ as a Clinical Evaluative Process for Existing Data in Oncology
Authors: Edward C. Li, Jessica DeMartino
Journal: Journal of the National Comprehensive Cancer Network (2010)

The National Comprehensive Cancer Network (NCCN) develops and communicates the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) to oncologists and other clinicians. The NCCN Guidelines are widely recognized and applied as the standard for clinical policy in the United States. These guidelines and related documents, such as the NCCN Drugs & Biologics Compendium (NCCN Compendium), are used extensively by public and private payors as the basis for the setting of coverage policies. Given the demand for comparative effectiveness (CE) analyses, as described and discussed in this report, the NCCN has begun work on a paradigm to integrate evidence-based CE analysis into the NCCN Guidelines deliberative process. This report presents NCCN's initial thinking on the use of NCCN expert panel members in developing a process that can be used to compare health care technologies (e.g., radiation modalities, chemotherapy regimens) in a formal, systematic way. Draft considerations are provided to stimulate discussion and feedback, particularly in the oncology community, as NCCN moves through processes such as methodologic review, validation of rating scales, and review of implications for public policy, toward finalization of an NCCN CE analytic paradigm.
ATP Depletion Increases Tyrosine Phosphorylation of β-Catenin and Plakoglobin in Renal Tubular Cells
Authors: JOHN H. SCHWARTZ, THEODORA SHIH, SARAH A. MENZA, WILFRED LIEBERTHAL
Journal: Journal of the American Society of Nephrology (1999)

Abstract. This study examines the hypothesis that the loss of integrity of the junctional complex induced by ATP depletion is related to alterations in tyrosine phosphorylation of the adherens junction proteins β-catenin and plakoglobin. ATP depletion of cultured mouse proximal tubular (MPT) cells induces a marked increase in tyrosine phosphorylation of both β-catenin and plakoglobin. The tyrosine phosphatase inhibitor vanadate has the same effect in ATP-replete (control) monolayers, whereas genistein, a tyrosine kinase inhibitor, reduces phosphorylation of both proteins in ATP-replete monolayers and prevents the hyperphosphorylation of these proteins with ATP depletion. This study also demonstrates that the fall in the transepithelial resistance of MPT monolayers induced by ATP depletion can be reproduced by treatment of ATP-replete monolayers with vanadate, whereas genistein substantially ameliorates the fall in transepithelial resistance induced by ATP depletion. Also, using immunofluorescence microscopy it was demonstrated that ATP depletion results in a marked diminution of E-cadherin staining in the basolateral membrane of MPT cells. Vanadate mimics this effect of ATP depletion, whereas genistein ameliorates the reduction in the intensity of E-cadherin staining induced by ATP depletion. Because it is has been well established that hyperphosphorylation of the catenins leads to dissociation of the adherens junction and to dysfunction of the junctional complex, it is proposed that the increase in tyrosine phosphorylation of catenins observed in MPT cells during ATP depletion contributes to the loss of function of the junctional complex associated with sublethal injury.
WFNO/SNO Abstracts
Journal: Neuro-Oncology (2001)

BACKGROUND: The treatment of patients with primary CNS lymphomas (PCNSL) has dramatically changed since the 1970’s when whole brain radiation generated median survivals of about 12 months, significant neurotoxcity, and few long term survivors. High dose methotrexate (HD-MTX) monotherapy without radiation provides excellent response rates and 30% long term survivors without neurotoxicity. In general, relapses occur in the first two to four years after diagnosis and reports of very late relapses are rare. METHODS: Charts of all patients treated with HD-MTX monotherapy for newly diagnosed PCNSL between 1995 and 2012 at The Johns Hopkins Hospital were reviewed retrospectively. Patients with less than 5 years of follow-up data were excluded. First relapses over 10 years from diagnosis were identified and reviewed. RESULTS: Long-term follow-up data was available for 37 patients treated with HD-MTX monotherapy during this period. Four of 37 (11%) survived disease free for .10 years from initial diagnosis and maintain their excellent clinical status. All received methotrexate (8 gm/ m 2 ) every two weeks until complete response and then monthly to complete one year of therapy. Two of these long survivors (50%) presented with new seizures 10.8 and 11.2 years after initial diagnosis. Imaging revealed recurrent intraparenchymal disease, re-biopsy confirmed PCNSL in one, and both responded very well to retreatment with high dose methotrexate and Rituximab. The other two patients remain relapse free 12 and 13.7 years after initial diagnosis. CONCLUSION: Very late relapses have occurred in 2 of 4 long term survivors. These observations suggest that PCNSL patients treated with HD-MTX who were considered cured may be at substantial risk for late recurrences. A concerted effort to follow patients with this rare disease is needed to determine the frequency of late recurrences. More information is needed to determine if the addition of rituximab or other therapies reduce late recurrence rates.
Critical Roles of STAT3 in β-Adrenergic Functions in the Heart
Authors: Wenjun Zhang, Xiuxia Qu, Biyi Chen, Marylynn Snyder, Meijing Wang, Baiyan Li, Yue Tang, Hanying Chen, Wuqiang Zhu, Li Zhan, Ni Yin, Deqiang Li, Li Xie, Ying Liu, J. Jillian Zhang, Xin-Yuan Fu, Michael Rubart, Long-Sheng Song, Xin-Yun Huang, Weinian Shou
Journal: Circulation (2015)

Background— β-Adrenergic receptors (βARs) play paradoxical roles in the heart. On one hand, βARs augment cardiac performance to fulfill the physiological demands, but on the other hand, prolonged activations of βARs exert deleterious effects that result in heart failure. The signal transducer and activator of transcription 3 (STAT3) plays a dynamic role in integrating multiple cytokine signaling pathways in a number of tissues. Altered activation of STAT3 has been observed in failing hearts in both human patients and animal models. Our objective is to determine the potential regulatory roles of STAT3 in cardiac βAR-mediated signaling and function. Methods and Results— We observed that STAT3 can be directly activated in cardiomyocytes by β-adrenergic agonists. To follow up this finding, we analyzed βAR function in cardiomyocyte-restricted STAT3 knockouts and discovered that the conditional loss of STAT3 in cardiomyocytes markedly reduced the cardiac contractile response to acute βAR stimulation, and caused disengagement of calcium coupling and muscle contraction. Under chronic β-adrenergic stimulation, Stat3cKO hearts exhibited pronounced cardiomyocyte hypertrophy, cell death, and subsequent cardiac fibrosis. Biochemical and genetic data supported that Gα s and Src kinases are required for βAR-mediated activation of STAT3. Finally, we demonstrated that STAT3 transcriptionally regulates several key components of βAR pathway, including β 1 AR, protein kinase A, and T-type Ca 2+ channels. Conclusions— Our data demonstrate for the first time that STAT3 has a fundamental role in βAR signaling and functions in the heart. STAT3 serves as a critical transcriptional regulator for βAR-mediated cardiac stress adaption, pathological remodeling, and heart failure.
The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation
Authors: S S Tarighat, R Santhanam, D Frankhouser, H S Radomska, H Lai, M Anghelina, H Wang, X Huang, L Alinari, A Walker, M A Caligiuri, C M Croce, L Li, R Garzon, C Li, R A Baiocchi, G Marcucci
Journal: Leukemia (2015)
Striving for Palliative Care From the Early Stage of Cancer Therapy
Authors: Yoshikazu Hasegawa, Hiroshi Tsukuda, Masatomo Otsuka, Kimio Yonesaka, Tomohiro Suzumura, Takamune Sugiura, Rikako Iwaya, Izumi Kawaguchi, Tomi Tanaka, Masahiro Fukuoka
Journal: Annals of Oncology (2014)
Non-Hodgkin’s Lymphomas, Version 1.2013
Authors: Andrew D. Zelenetz, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Barbara Pro, Nishitha Reddy, Lubomir Sokol, Lode Swinnen, Christina Tsien, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary A. Dwyer, Maoko Naganuma
Journal: Journal of the National Comprehensive Cancer Network (2013)

These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Non-Hodgkin's Lymphomas (NHL) and provide a discussion of the clinical evidence that support the updates. The updates discussed in this article feature recommendations for additional treatment options in patients with chronic lymphocytic leukemia and guidance surrounding the management of hepatitis virus reactivation/infections in high-risk patients with NHL undergoing antitumor therapy.
Phase I study of TH-302, an investigational hypoxia-targeted drug, and dexamethasone in patients with relapsed/refractory multiple myeloma.
Authors: Irene M. Ghobrial, Jacob Laubach, Philippe Armand, Erica Boswell, Courtney Hanlon, Stacey Chuma, Esther Dawn Chu, Damian Handisides, Stew Kroll, Barbara Hickingbottom, Kenneth Carl Anderson, Paul Gerard Guy Richardson
Journal: Journal of Clinical Oncology (2013)

8602 Background: TH-302 is an investigational 2-nitroimidazole prodrug of the DNA alkylator Br-IPM designed to be selectively activated in hypoxia. In multiple myeloma (MM) mouse models, diseased animals demonstrate a marked expansion of areas of hypoxia in the bone marrow. TH-302 exhibited anti-tumor activity against MM in vitro and in vivo and synergism was seen when combined with bortezomib (Hu et al, Blood 2010; Chesi et al, Blood 2012). Based on these findings, a phase I/II study of TH-302 plus dexamethasone (dex) was initiated for patients (pts) with relapsed/refractory MM. Methods: Eligible pts in the study (NCT01522872) had ECOG PS ≤ 2, receipt of at least two prior therapies, and acceptable hepatorenal function and hematologic status. A standard 3+3 dose escalation design was used with a fixed oral 40 mg dose of dex and 40% dose increments of TH-302. TH-302 was administered IV with dex on days 1, 4, 8, and 11 of a 21-day cycle. The objectives were to determine DLTs and the MTD; assess the safety, tolerability and preliminary clinical activity of TH-302 plus dex; and study the relationship between hypoxia within the bone marrow and response to TH-302. Results: Eleven pts have been treated: 7M/4F with a median age 61 years (range: 53 – 86) and 6 prior therapies (range: 3 – 10). All received both bortezomib and lenalidomide/thalidomide containing regimens. TH-302 was dosed at 240 (n=5), 340 (n=4), and 480 (n=2) mg/m² for a median of 5 cycles. No DLTs were reported at 240 or 340 mg/m². Two pts treated at 480 mg/m² had DLTs of grade 3 mucositis, exceeding the definition of MTD. A dose expansion is thus ongoing at 340 mg/m 2 . Two patients had SAEs related to TH-302 (pneumonia). Five pts continue on study after a median of 7 cycles (range: 2–11). Nine pts have had efficacy evaluations: 2 pts with partial responses, 2 pts with minimal responses, and 5 pts with stable disease, for an overall response rate (of MR or better) of 44%. Conclusions: TH-302 can be administered at 340 mg/m 2 biweekly + dex, with dose limiting mucositis seen at higher doses. Initial clinical activity has been noted with an ORR of 44% in heavily pretreated MM pts who are relapsed/refractory to both bortezomib and lenalidomide. Clinical trial information: NCT01522872.
Superficial Venous Thrombosis and Venous Thromboembolism
Authors: Hervé Decousus, Isabelle Quéré, Emilie Presles, François Becker, Marie-Thérèse Barrellier, Myriam Chanut, Jean-Luc Gillet, Hervé Guenneguez, Christine Leandri, Patrick Mismetti, Olivier Pichot, Alain Leizorovicz
Journal: Annals of Internal Medicine (2010)

Decousus and colleagues assessed the prevalence and incidence of venous thromboembolism in 844 patients with superficial venous thrombosis who were evaluated by vein specialists in France. About 25...
5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients
Authors: H.H.J. Backus, D.F. Dukers, C.J. van Groeningen, W. Vos, E. Bloemena, D. Wouters, J.M.G.H. van Riel, K. Smid, G. Giaccone, H.M. Pinedo, G.J. Peters
Journal: Annals of Oncology (2001)
Uptake and Metabolism of <sup>14</sup> C-Labeled Oleic Acid by Atherosclerotic Lesions in Rabbit Aorta
Authors: ALLAN J. DAY, MARK L. WAHLQVIST
Journal: Circulation Research (1968)

The uptake of 14 C-labeled oleic acid and its incorporation into combined lipids by aortic intimas from normal and cholesterol-fed rabbits has been investigated in vitro. More than five times as much oleic acid was taken up by the atherosclerotic intima as by the normal intima. About twice as much oleic acid was incorporated into phospholipid, and twenty times as much into cholesterol ester by the atherosclerotic intima as by the normal. Lecithin was the major phospholipid synthesized from oleic acid in both normal and atherosclerotic intimas. Radioautographs of the atherosclerotic vessels show that the 14 C-labeled oleic acid and its metabolic derivatives, principally phospholipid and cholesterol ester, were localized in sudanophilic cells in the intima in both early and advanced lesions. It is concluded that intimal foam cells are primarily responsible for the lipid synthesis that occurs in the atherosclerotic lesion.
The utility of multiple molecular methods including whole genome sequencing as tools to differentiate Escherichia coli O157:H7 outbreaks
Authors: Byron M Berenger, Chrystal Berry, Trevor Peterson, Patrick Fach, Sabine Delannoy, Vincent Li, Lorelee Tschetter, Celine Nadon, Lance Honish, Marie Louie, Linda Chui
Journal: Eurosurveillance (2015)

A standardised method for determining Escherichia coli O157:H7 strain relatedness using whole genome sequencing or virulence gene profiling is not yet established. We sought to assess the capacity of either high-throughput polymerase chain reaction (PCR) of 49 virulence genes, core-genome single nt variants (SNVs) or k-mer clustering to discriminate between outbreak-associated and sporadic E. coli O157:H7 isolates. Three outbreaks and multiple sporadic isolates from the province of Alberta, Canada were included in the study. Two of the outbreaks occurred concurrently in 2014 and one occurred in 2012. Pulsed-field gel electrophoresis (PFGE) and multilocus variable-number tandem repeat analysis (MLVA) were employed as comparator typing methods. The virulence gene profiles of isolates from the 2012 and 2014 Alberta outbreak events and contemporary sporadic isolates were mostly identical; therefore the set of virulence genes chosen in this study were not discriminatory enough to distinguish between outbreak clusters. Concordant with PFGE and MLVA results, core genome SNV and k-mer phylogenies clustered isolates from the 2012 and 2014 outbreaks as distinct events. k-mer phylogenies demonstrated increased discriminatory power compared with core SNV phylogenies. Prior to the widespread implementation of whole genome sequencing for routine public health use, issues surrounding cost, technical expertise, software standardisation, and data sharing/comparisons must be addressed.
Addressing the Needs of Children in a Time of Health Reform via Medicaid, CHIP, or Subsidized Markets
Authors: David M. Keller
Journal: JAMA Pediatrics (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Female contraception over 40
Journal: Human Reproduction Update (2009)

BACKGROUNDThe majority of women 40–49 years of age need an effective method of contraception because the decline in fertility with age is an insufficient protection against unwanted pregnancy. Although pregnancy is less likely after the age of 40 years, the clinical and social consequences of an unexpected pregnancy are potentially detrimental. No contraceptive method is contraindicated by advanced reproductive age alone; thus there is a need to discuss the effectiveness, risks and non-contraceptive benefits of all family planning methods for women in this age group.
Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy
Authors: W. Scheithauer, G.V. Kornek, B. Schuell, H. Ulrich-Pur, M. Penz, M. Raderer, F. Lang, B. Schneeweiss, A. Lenauer, D. Depisch
Journal: Annals of Oncology (2001)
In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotides
Authors: Gaetan Billioud, Robert L. Kruse, Melissa Carrillo, Christina Whitten-Bauer, Dacao Gao, Aneeza Kim, Leon Chen, Michael L. McCaleb, Jeffrey R. Crosby, Robert Hamatake, Zhi Hong, Urtzi Garaigorta, Eric Swayze, Karl-Dimiter Bissig, Stefan Wieland
Journal: Journal of Hepatology (2015)